Short Communication | Published:

CyclinD-CDK4/6 complexes phosphorylate CDC25A and regulate its stability

Oncogene volume 36, pages 37813788 (29 June 2017) | Download Citation

Abstract

The phosphatase CDC25A is a key regulator of cell cycle progression by dephosphorylating and activating cyclin-CDK complexes. CDC25A is an unstable protein expressed from G1 until mitosis. CDC25A overexpression, which can be caused by stabilization of the protein, accelerates the G1/S and G2/M transitions, leading to genomic instability and promoting tumorigenesis. Thus, controlling CDC25A protein levels by regulating its stability is a critical mechanism for timing cell cycle progression and to maintain genomic integrity. Herein, we show that CDC25A is phosphorylated on Ser40 throughout the cell cycle and that this phosphorylation is established during the progression from G1 to S phase. We demonstrate that CyclinD-CDK4/CDK6 complexes mediate the phosphorylation of CDC25A on Ser40 during G1 and that these complexes directly phosphorylate this residue in vitro. Importantly, we also find that CyclinD1-CDK4 decreases CDC25A stability in a ßTrCP-dependent manner and that Ser40 and Ser88 phosphorylations contribute to this regulation. Thus our results identify cyclinD-CDK4/6 complexes as novel regulators of CDC25A stability during G1 phase, generating a negative feedback loop allowing control of the G1/S transition.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from $8.99

All prices are NET prices.

References

  1. 1.

    , , . The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol 2006; 18: 185–191.

  2. 2.

    , , , , , et al. CDC25A targeting by miR-483-3p decreases CCND-CDK4/6 assembly and contributes to cell cycle arrest. Cell Death Differ 2013; 20: 800–811.

  3. 3.

    , . The role of Cdc25A in the regulation of cell proliferation and apoptosis. Anticancer Agents Med Chem 2012; 12: 631–639.

  4. 4.

    , , , , , . TGF-beta-induced RhoA and p160ROCK activation is involved in the inhibition of Cdc25A with resultant cell-cycle arrest. Proc Natl Acad Sci USA 2003; 100: 15548–15553.

  5. 5.

    , , , , , et al. Cell adhesion regulates CDC25A expression and proliferation in acute myeloid leukemia. Cancer Res 2006; 66: 7128–7135.

  6. 6.

    , , , , . Cell cycling through Cdc25A: transducer of cytokine proliferative signals. Cell Cycle 2006; 5: 907–912.

  7. 7.

    , , , , , et al. Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res 2007; 67: 6605–6611.

  8. 8.

    , , , , , et al. Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. Cancer Res 2007; 67: 984–991.

  9. 9.

    , , . CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 2007; 7: 495–507.

  10. 10.

    , . Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases. Mol Cell Biol 1999; 19: 6183–6194.

  11. 11.

    , , , , . Cdc25 phosphatases are required for timely assembly of CDK1-cyclin B at the G2/M transition. J Biol Chem 2010; 285: 16978–16990.

  12. 12.

    , , , , , . Regulation of G(2)/M events by Cdc25A through phosphorylation-dependent modulation of its stability. EMBO J 2002; 21: 5911–5920.

  13. 13.

    , , . CDC25A: a rebel within the CDC25 phosphatases family? Anticancer Agents Med Chem 2008; 8: 825–831.

  14. 14.

    , , . Activation of the phosphatase activity of human cdc25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J 1994; 13: 4302–4310.

  15. 15.

    , , , , , et al. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 2003; 426: 87–91.

  16. 16.

    , , , , , et al. SCFbeta-TRCP links Chk1 signaling to degradation of the Cdc25A protein phosphatase. Genes Dev 2003; 17: 3062–3074.

  17. 17.

    , . Cdk2 is required for p53-independent G2/M checkpoint control. PLoS Genet 2010; 6: e1000863.

  18. 18.

    , . Regulation of Cdc25A half-life in interphase by cyclin-dependent kinase 2 activity. J Biol Chem 2003; 278: 31838–31842.

  19. 19.

    , , , , , et al. The extracellular signal-regulated kinase-mitogen-activated protein kinase pathway phosphorylates and targets Cdc25A for SCF beta-TrCP-dependent degradation for cell cycle arrest. Mol Biol Cell 2009; 20: 2186–2195.

  20. 20.

    , , . Deregulated Cdk5 triggers aberrant activation of cell cycle kinases and phosphatases inducing neuronal death. J Cell Sci 2012; 125(Pt 21): 5124–5137.

  21. 21.

    , , , , . Human Cdc14B promotes progression through mitosis by dephosphorylating Cdc25 and regulating Cdk1/cyclin B activity. PLoS One 2011; 6: e14711.

  22. 22.

    , , , , , et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243: 527–536.

  23. 23.

    , , , , , et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3: 1427–1438.

  24. 24.

    , . Casein kinase 1 functions as both penultimate and ultimate kinase in regulating Cdc25A destruction. Oncogene 2010; 29: 3324–3334.

  25. 25.

    , , , , , et al. Targets of the cyclin-dependent kinase Cdk1. Nature 2003; 425: 859–864.

  26. 26.

    , , , , , et al. A human cancer-predisposing polymorphism in Cdc25A is embryonic lethal in the mouse and promotes ASK-1 mediated apoptosis. Cell Div 2011; 6: 4.

  27. 27.

    , . Many fingers on the mitotic trigger: post-translational regulation of the Cdc25C phosphatase. Cell Cycle 2004; 3: 41–45.

  28. 28.

    , . Pin1 acts catalytically to promote a conformational change in Cdc25. Mol Cell 2001; 7: 1071–1083.

  29. 29.

    , , , , , et al. CDC 25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma. Tumour Biol 2010; 31: 597–604.

  30. 30.

    , , . Beta-TrCP recognizes a previously undescribed nonphosphorylated destruction motif in Cdc25A and Cdc25B phosphatases. Proc Natl Acad Sci USA 2005; 102: 6279–6284.

  31. 31.

    , , , , . Oncogenic potential of a C. elegans cdc25 gene is demonstrated by a gain-of-function allele. EMBO J 2002; 21: 665–674.

  32. 32.

    , , , , , et al. Cytokine-driven cell cycling is mediated through Cdc25A. J Cell Biol 2005; 169: 755–763.

  33. 33.

    , , , , . SMG-1 suppresses CDK2 and tumor growth by regulating both the p53 and Cdc25A signaling pathways. Cell Cycle 2013; 12: 3770–3780.

  34. 34.

    , , , , , et al. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2. EMBO J 1996; 15: 7060–7069.

  35. 35.

    , . Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993; 262: 2050–2054.

  36. 36.

    , , , , , . Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci USA 1998; 95: 1392–1397.

  37. 37.

    , , , , , et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. J Neurosci 2005; 25: 2002–2009.

Download references

Acknowledgements

We thank H. Piwnica-Worms for providing phospho-Ser76, 82 and 88 CDC25A antibodies, V. Dulic for providing BJ-hTert cells and M. Gotanegre for technical assistance. This work was supported in part by grants to OBS from the Région Midi-Pyrénées, Toulouse Métropole and European funds FEDER (Fonds Européens de Développement Régional) for mass spectrometry.

Author information

Affiliations

  1. Cancer Research Center of Toulouse, INSERM UMR1037/Université Toulouse III Paul Sabatier, Toulouse, France

    • C Dozier
    • , L Mazzolini
    • , C Cénac
    • , A Besson
    •  & S Manenti
  2. Equipe labellisée Ligue Contre le Cancer, CNRS ERL5294, Toulouse, France

    • C Dozier
    • , L Mazzolini
    •  & S Manenti
  3. Institut de Pharmacologie et de Biologie Structurale, CNRS UMR5089, Université Toulouse, Toulouse, France

    • C Froment
    •  & O Burlet-Schiltz

Authors

  1. Search for C Dozier in:

  2. Search for L Mazzolini in:

  3. Search for C Cénac in:

  4. Search for C Froment in:

  5. Search for O Burlet-Schiltz in:

  6. Search for A Besson in:

  7. Search for S Manenti in:

Competing interests

The authors declare no conflict of interest.

Corresponding author

Correspondence to C Dozier.

Supplementary information

About this article

Publication history

Received

Revised

Accepted

Published

DOI

https://doi.org/10.1038/onc.2016.506

Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)